GTX Inc (GTXI) 0.59 $GTXI
GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:15AM CDT
GTx, Inc. (GTXI) shares rose almost 18% in the last trading session.
GTXI: 0.59 (unch), ANIP: 56.51 (-1.61)
GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference
BusinessWire - Thu Jun 02, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 9, 2016, at the Jefferies 2016 Global Healthcare Conference in New York City. The GTx presentation will begin at 10:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 23.
GTXI: 0.59 (unch)
GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016
BusinessWire - Mon May 16, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on May 24, 2016, at the UBS Global Healthcare Conference in New York City. The GTx presentation will begin at 11:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 7, 2016.
GTXI: 0.59 (unch)
GTx posts 1Q profit
Automated Insights - Tue May 10, 6:14AM CDT
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Tuesday reported first-quarter net income of $2.1 million, after reporting a loss in the same period a year earlier.
GTXI: 0.59 (unch)
GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming milestones. The Company is currently enrolling patients in three clinical trials: two trials evaluating enobosarm as a potential treatment for women with advanced breast cancer and another assessing enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.
GTXI: 0.59 (unch)
GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting
BusinessWire - Mon May 09, 6:00AM CDT
-- Novel SARD compounds being developed initially as a potential treatment for men with castration-resistant prostate cancer --
GTXI: 0.59 (unch)
GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed Apr 27, 6:00AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2016 financial results press release will be Tuesday, May 10, 2016, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
GTXI: 0.59 (unch)
GTx reports 4Q loss
Automated Insights - Thu Mar 03, 6:17AM CST
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Thursday reported a loss of $3.2 million in its fourth quarter.
GTXI: 0.59 (unch)
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Thu Mar 03, 6:00AM CST
-- Lead SARD candidates have been selected for additional preclinical studies necessary to initiate first in human clinical trials --
GTXI: 0.59 (unch)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.55 (-0.24), PFE: 36.12 (+0.35), OPHT: 55.07 (+1.55), PFNX: 8.84 (+0.21), OCUL: 5.94 (+0.60), AGN: 240.59 (+2.58), GTXI: 0.59 (unch), OHRP: 2.70 (-0.02), AAVL: 4.14 (-0.18), TCON: 4.98 (+0.19), REGN: 378.35 (+6.90), NVS: 82.13 (+0.33)
Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.59 (unch), AZN: 30.11 (unch), GALT: 1.56 (+0.04)
GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
BusinessWire - Wed Jan 13, 6:00AM CST
-- Objective to determine whether a SARM may increase pelvic floor muscle mass and potentially improve outcomes in women with SUI --
GTXI: 0.59 (unch)
Duchenne Muscular Dystrophy - Pipeline Review 2015
M2 - Wed Jan 06, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dsjbc/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - BioMarin Pharmaceutical Inc. - Bristol-Myers Squibb Company - Capricor Therapeutics, Inc. - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dong-A Socio Group - Editas Medicine, Inc. - Eli Lilly and Company - EryDel SPA - FibroGen, Inc. - Galapagos NV - Genethon - GTx, Inc. - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - La Jolla Pharmaceutical Company - (20 Others) For more information visit http://www.researchandmarkets.com/research/9d...e_muscular
GTXI: 0.59 (unch), CAPR: 4.02 (-0.07), BMRN: 91.49 (+3.33), IDRA: 1.68 (+0.04), FGEN: 17.76 (+0.63), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), GLPG: 55.23 (+0.28), XLRN: 34.75 (+0.84)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.59 (unch), LPTN: 1.75 (-0.08)
Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session
Zacks Equity Research - Zacks Investment Research - Wed Dec 16, 7:20AM CST
GTX Inc. (GTXI) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
GTXI: 0.59 (unch), ACHN: 9.14 (+0.26)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 8.61 (+0.04), EBS: 30.04 (+0.46), ARWR: 5.73 (+0.17), AMBX: (), PFE: 36.12 (+0.35), ADMP: 3.28 (+0.18), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BIND: 0.56 (+0.01), GSK: 43.38 (+0.04), BMY: 75.28 (+1.20), MDVN: 62.10 (-0.64), PGNX: 5.47 (+0.03), GTXI: 0.59 (unch), AZN: 30.11 (unch), NLNK: 11.79 (+0.17), ABBV: 64.16 (+0.73)
GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:15AM CDT
GTx, Inc. (GTXI) shares rose almost 18% in the last trading session.
GTXI: 0.59 (unch), ANIP: 56.51 (-1.61)
GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference
BusinessWire - Thu Jun 02, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 9, 2016, at the Jefferies 2016 Global Healthcare Conference in New York City. The GTx presentation will begin at 10:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 23.
GTXI: 0.59 (unch)
GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016
BusinessWire - Mon May 16, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on May 24, 2016, at the UBS Global Healthcare Conference in New York City. The GTx presentation will begin at 11:30 am EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 7, 2016.
GTXI: 0.59 (unch)
GTx posts 1Q profit
Automated Insights - Tue May 10, 6:14AM CDT
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Tuesday reported first-quarter net income of $2.1 million, after reporting a loss in the same period a year earlier.
GTXI: 0.59 (unch)
GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming milestones. The Company is currently enrolling patients in three clinical trials: two trials evaluating enobosarm as a potential treatment for women with advanced breast cancer and another assessing enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.
GTXI: 0.59 (unch)
GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting
BusinessWire - Mon May 09, 6:00AM CDT
-- Novel SARD compounds being developed initially as a potential treatment for men with castration-resistant prostate cancer --
GTXI: 0.59 (unch)
GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed Apr 27, 6:00AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2016 financial results press release will be Tuesday, May 10, 2016, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
GTXI: 0.59 (unch)
GTx reports 4Q loss
Automated Insights - Thu Mar 03, 6:17AM CST
MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Thursday reported a loss of $3.2 million in its fourth quarter.
GTXI: 0.59 (unch)
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Thu Mar 03, 6:00AM CST
-- Lead SARD candidates have been selected for additional preclinical studies necessary to initiate first in human clinical trials --
GTXI: 0.59 (unch)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.55 (-0.24), PFE: 36.12 (+0.35), OPHT: 55.07 (+1.55), PFNX: 8.84 (+0.21), OCUL: 5.94 (+0.60), AGN: 240.59 (+2.58), GTXI: 0.59 (unch), OHRP: 2.70 (-0.02), AAVL: 4.14 (-0.18), TCON: 4.98 (+0.19), REGN: 378.35 (+6.90), NVS: 82.13 (+0.33)
Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.59 (unch), AZN: 30.11 (unch), GALT: 1.56 (+0.04)
GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
BusinessWire - Wed Jan 13, 6:00AM CST
-- Objective to determine whether a SARM may increase pelvic floor muscle mass and potentially improve outcomes in women with SUI --
GTXI: 0.59 (unch)
Duchenne Muscular Dystrophy - Pipeline Review 2015
M2 - Wed Jan 06, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dsjbc/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - BioMarin Pharmaceutical Inc. - Bristol-Myers Squibb Company - Capricor Therapeutics, Inc. - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dong-A Socio Group - Editas Medicine, Inc. - Eli Lilly and Company - EryDel SPA - FibroGen, Inc. - Galapagos NV - Genethon - GTx, Inc. - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - La Jolla Pharmaceutical Company - (20 Others) For more information visit http://www.researchandmarkets.com/research/9d...e_muscular
GTXI: 0.59 (unch), CAPR: 4.02 (-0.07), BMRN: 91.49 (+3.33), IDRA: 1.68 (+0.04), FGEN: 17.76 (+0.63), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), GLPG: 55.23 (+0.28), XLRN: 34.75 (+0.84)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.59 (unch), LPTN: 1.75 (-0.08)
Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session
Zacks Equity Research - Zacks Investment Research - Wed Dec 16, 7:20AM CST
GTX Inc. (GTXI) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
GTXI: 0.59 (unch), ACHN: 9.14 (+0.26)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 8.61 (+0.04), EBS: 30.04 (+0.46), ARWR: 5.73 (+0.17), AMBX: (), PFE: 36.12 (+0.35), ADMP: 3.28 (+0.18), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BIND: 0.56 (+0.01), GSK: 43.38 (+0.04), BMY: 75.28 (+1.20), MDVN: 62.10 (-0.64), PGNX: 5.47 (+0.03), GTXI: 0.59 (unch), AZN: 30.11 (unch), NLNK: 11.79 (+0.17), ABBV: 64.16 (+0.73)
